SIGA develops medicines to prevent and treat emerging infectious diseases with high unmet medical needs. The company is focused on orthopoxviruses, including smallpox and mpox.

SIGA

SIGA Technologies | 3,321 followers on LinkedIn. SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs. Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone. Smallpox, mpox, and other orthopoxviruses are particularly worrisome because they are highly infectious and deadly.

Antonio Rubens da Silva Filho

IT Leader with expertise in tech growth, transformation, and business development. Skilled in driving tech initiatives, team building & leadership…

Ed O.

Associate Director, Animal Studies, Poxvirus Research at SIGA Technologies Inc.

Andrew Russo

Senior Leader in Regulatory and Quality BioPharma

Kristin Murray

SIGA Technologies

We’re pleased to see continued focus on pandemic preparedness with the recent conclusion of The Pandemic Fund ’s second funding round. The Governing Board's commitment to granting resources aimed at enhancing prevention, preparedness, and response (PPR) capabilities across 50 countries is a vital step forward. At SIGA, we recognize the critical importance of PPR as we work to develop medicines to treat and prevent emerging #infectiousdiseases . By supporting initiatives that strengthen our collective capacity to detect, respond to, and prevent outbreaks, we are taking significant strides towards safeguarding #globalhealth .

#Infectiousdiseases pose a severe threat to #globalhealth that cannot be adequately addressed with vaccines alone. Among these, #smallpox , #mpox , and other orthopoxviruses stand out due to their high infectivity and lethality. Society must take proactive measures to prevent and mitigate outbreaks—whether they arise from natural occurrences, accidents, or intentional acts. At SIGA, we are dedicated to developing treatments to combat emerging infectious diseases with high unmet medical need, ensuring patients worldwide receive the care they need. Learn more: https://www.siga.com/

This #VeteransDay , we honor and express our heartfelt gratitude to the brave men and women who have served and continue to serve our country. We are proud to partner with the U.S. Department of Defense and provide our antiviral medicine to protect and support our military personnel. Ensuring the safety and well-being of our troops is essential, and we are committed to safeguarding those who serve.

Today we announced our third quarter 2024 financial results. Join our management team for a conference call and webcast at 4:30pm ET: https://lnkd.in/enPd4C-E

Today we announced that our management team will host a webcast and conference call to provide a business update at 4:30pm ET on November 7. See our press release: https://lnkd.in/eX52sZVg

Today we announced an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mAbs) with potential applications in a broad range of orthopoxviruses. Learn more in our press release: https://lnkd.in/ecd3xHyJ

Last week, our VP and Head of International Markets, Victor Gomes, MBA , had the privilege of attending the Health Emergency Preparedness and Response Authority (HERA) #InfoDay in Budapest. As we develop medicines to prevent and treat emerging #infectiousdiseases with high unmet medical needs, it was a pleasure to connect with global health leaders to exchange insights and discuss opportunities for collaboration between private sector, member states and health authorities for enhancing #healthsecurity . Thank you to EU in Emergencies and the European Commission for facilitating these important discussions!

Today we announced that we entered an agreement to supply our antiviral therapy in Morocco in response to a request from the Ministry of Health to help prepare and protect its citizens. We are proud to reaffirm our commitment to global #healthsecurity . See the full press release: https://lnkd.in/e9Wtrz6x

The escalating #mpox outbreak is raising alarms about a potential multi-country epidemic or even a new pandemic. This year alone, over 17,000 suspected cases have been reported across Africa, predominantly in the Democratic Republic of the Congo, underscoring the critical importance of a unified global response to combat the spread. In this JAMA publication, senior scholars from Johns Hopkins Center for Health Security examine the current global governance framework for a public health emergency of international concern (PHEIC), assess the mpox outbreak in Africa, and underscore the urgent need for countries to take swift action in response to this international call. See here: https://lnkd.in/enzvjjtf @Caitlin Rivers @Crystal Watson @Alexandra Phelan

Since the World Health Organization declared #mpox a public health emergency of international concern ( #PHEIC ) last month, two people traveling to Africa – one from Sweden and one from Thailand – have become infected with the clade Ib virus and brought it back to their home countries. As mpox spreads rapidly, Nature spoke with #infectiousdisease specialists to explore how this current emergency compares to the global outbreak of 2022 and how the clade Ib strain differs from the clade II strain that caused the earlier outbreak. Stay informed about the mpox outbreak and its impact on #publichealth : https://lnkd.in/gh4uM8jV

Baby Video Maker

Photo Love Frame

Photo art collage Editor

Choose Photo Live Wallpaper 3D

Valentine Photo Collage Free

Blur Photo Square

Funny Photo Montage Suit

Lovely Photo Collage

Eye Color Changer

Reverse video

Domain Not Resolving

Gravity Forms

ASP.NET Ajax

Comcast

Google Analytics IP Anonymization

Cogent Communications

EVP and Chief Financial Officer

Daniel Luckshire

Board of Directors

Jim Antal

Phil Gomez

VP Controller

Kevin Buckley

Vice President of Corporate Strategy & Business Development

Marianna Anesti

SVP, Operations & Chief Supply Chain Officer

Tove Bolken

Associate Director of Animal Studies

Director of Business Development

Ben Novak

Associate Director, Contracts & Project Management

Candace Lovejoy

Senior Director, Poxvirus Research

Doug Grosenbach

Robin Abrams

Chief Administrative Officer and General Counsel

Susan K Burgess

President

Judson A. Cooper

Founder

Jay K. Varma

Executive Vice President, Chief Medical Officer

Diem Nguyen

Dennis E. Hruby

Chief Scientific Officer

Northeastern US Companies (Top 10K)

Biotechnology Companies With Fewer Than 50 Employees (Top 10K)

New York Companies With Fewer Than 50 Employees (Top 10K)

Greater New York Area Companies With Fewer Than 50 Employees (Top 10K)

SIGA is a pharmaceutical company specializing in the development of pharmaceutical solutions for some of the most lethal pathogens – variola (smallpox), Ebola, dengue, Lassa fever and other dangerous viruses. Our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats.  Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures.

U.S. Department of Defense

Grant - SIGA Technologies

Post-IPO Equity - SIGA Technologies

National Institutes of Health

MacAndrews & Forbes, Incorporated

New York

United States

North America

SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman

SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results

First mpox case linked to African outbreak reported in U.K.

SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating SIGA Technologies, Inc. for potential violations of federal securities laws

SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies

Siga Technologies exercises option to license orthopoxvirus monoclonal antibodies from Vanderbilt University

Siga Technologies enters exclusive license agreement with Vanderbilt University

Siga Technologies to supply mpox therapy in Morocco

An antiviral drug approved for the treatment of smallpox, also approved for treatment of monkeypox, cowpox, and vaccinia complications in various regions.

An intravenous formulation of TPOXX for smallpox treatment in patients unable to swallow oral capsules.

Brazil

South America

India

Asia

Pakistan

Portugal

Europe

HTML5

Google Fonts

F5 NGINX

Apache Server

Office 365

Modernizr

Google Analytics

Google Compute Engine

jQuery

Symantec Email Security.Cloud

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

news impact assignment basic	general
public peers	general	Nov 17, 2024 12:56 AM	01af5dc0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 12:56 AM	45dde27f
crunchbase trigger	general	Nov 17, 2024 12:56 AM	c6ad712f
crunchbase profile	general	Nov 17, 2024 1:12 AM	f2db86e3
li profile	general	Nov 17, 2024 12:56 AM	ac377e35
translate crunchbase fundingrounds	general	Nov 17, 2024 1:33 AM	8593192c
peers	general	Nov 17, 2024 12:56 AM	5e6e16ca
news basic	general	Nov 17, 2024 12:56 AM	758e0ed5
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:SIGA

SIGA

Last Close

6.27

22/11 21:00

Market Cap

606.67M

Beta: -

Volume Today

313.84K

Avg: -